Insmed Incorporated (NASDAQ:INSM) Given Average Recommendation of “Buy” by Analysts

Shares of Insmed Incorporated (NASDAQ:INSM) have been given an average rating of “Buy” by the sixteen analysts that are currently covering the company, Marketbeat reports. Sixteen investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have covered the stock in the last year is $94.00.

INSM has been the subject of a number of research reports. Bank of America raised their target price on Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. raised their target price on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday, February 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. HC Wainwright restated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Friday, February 21st. Finally, Stifel Nicolaus lowered their target price on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, February 21st.

Insider Buying and Selling at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 6,172 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08. Following the transaction, the insider now owns 101,549 shares of the company’s stock, valued at $6,462,578.36. The trade was a 5.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50. Following the transaction, the chief executive officer now directly owns 334,186 shares in the company, valued at $25,742,347.58. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 550,957 shares of company stock worth $42,992,528. Corporate insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in INSM. California State Teachers Retirement System grew its holdings in Insmed by 4.5% in the 4th quarter. California State Teachers Retirement System now owns 153,343 shares of the biopharmaceutical company’s stock valued at $10,587,000 after buying an additional 6,601 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in Insmed by 10.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 3,231 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 307 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Insmed in the 4th quarter valued at $6,798,000. Mackenzie Financial Corp grew its holdings in Insmed by 12.5% in the 4th quarter. Mackenzie Financial Corp now owns 10,883 shares of the biopharmaceutical company’s stock valued at $751,000 after buying an additional 1,213 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in Insmed in the 4th quarter valued at $259,000.

Insmed Stock Up 1.5 %

Shares of NASDAQ INSM opened at $79.92 on Friday. The stock has a market cap of $14.47 billion, a PE ratio of -14.30 and a beta of 1.28. The business has a fifty day moving average of $77.43 and a two-hundred day moving average of $73.80. Insmed has a 52-week low of $21.92 and a 52-week high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. As a group, equities research analysts expect that Insmed will post -4.56 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.